Nanna Lüneborg

‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid

Global biopharma M&A is experiencing a sharp uptick, putting the sector on track for its strongest year since the pre-pandemic peak seven years ago. Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking so far in 2026 amounted to $106 billion over 201 deals, according to PitchBook data. If the current pace of biopharma M&A holds up for the rest of the year, the industry could be on track to notch more than $250 billion in...